Neuroblastoma Therapeutics Pipeline Analysis 2017 – Collaboration and Other Developments

Neuroblastoma

The neuroblastoma therapeutics pipeline is expected to witness considerable growth in the future due to high prevalence of tumour in children. According to the American Cancer Society, around 7.0% of total cancer cases occurred in the age group of 0 to 14, observed as neuroblastoma, with most of the cases being reported at an age of 2 to 3 years. There are various immunotherapies and targeted drug therapies that are being developed for treatment of neuroblastoma which are expected to further lead to the growth of its pipeline in the future.

Explore Report at: https://www.psmarketresearch.com/market-analysis/neuroblastoma-therapeutics-pipeline-analysis

Neuroblastoma is the most common type of cancer found in children, diagnosed mostly at the age of 1 year, characterized by broad range of clinical behavior. Neuroblastoma is derived from primordial neural crest cell which ultimately present into the sympathetic ganglia and adrenal medulla. It has been stated that the chances of survival in an event free from neuroblastoma are less than 50.0%. Neuroblastoma in chest can cause wheezing, chest pain, drooping eyelids and unequal pupils. The disease usually metastasized in bone marrow, skin, liver and bones until it is diagnosed. Abdominal pain, swelling in legs and altered bowel habits are the common symptoms of abdominal neuroblastoma. Fever, shortness of breath, high blood pressure, watery diarrhea and uncontrolled eye movement are the less common symptoms of neuroblastoma. Scientist have also concluded that neuroblastoma can also occurs due to genetic mutation. The elevation of level of urinary catecholamine is the primary evidence of neuroblastoma.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/neuroblastoma-therapeutics-pipeline-analysis/toc-sample

Some of the key players having a pipeline of neuroblastoma therapeutics include AstraZeneca Plc, Celgene Corporation, Progenics Pharmaceuticals, Inc., Novartis AG, Abbvie, Inc., MabVax Therapeutics Holdings, Inc., Pfizer Inc., Syros Pharmaceuticals, Inc., Array BioPharma, and Takeda Pharmaceutical Company Limited.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s